Alps Advisors Inc. Sells 28,353 Shares of AlloVir, Inc. (NASDAQ:ALVR)

Alps Advisors Inc. trimmed its stake in AlloVir, Inc. (NASDAQ:ALVRGet Rating) by 42.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,808 shares of the company’s stock after selling 28,353 shares during the quarter. Alps Advisors Inc. owned approximately 0.06% of AlloVir worth $151,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Amalgamated Bank bought a new position in AlloVir in the first quarter valued at approximately $33,000. Swiss National Bank grew its stake in AlloVir by 7.5% in the first quarter. Swiss National Bank now owns 84,800 shares of the company’s stock valued at $572,000 after purchasing an additional 5,900 shares in the last quarter. MetLife Investment Management LLC grew its stake in AlloVir by 51.5% in the first quarter. MetLife Investment Management LLC now owns 18,052 shares of the company’s stock valued at $122,000 after purchasing an additional 6,136 shares in the last quarter. Jane Street Group LLC bought a new position in AlloVir in the first quarter valued at approximately $69,000. Finally, JPMorgan Chase & Co. grew its stake in AlloVir by 1.6% in the second quarter. JPMorgan Chase & Co. now owns 775,807 shares of the company’s stock valued at $3,027,000 after purchasing an additional 11,899 shares in the last quarter. 38.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on ALVR shares. Morgan Stanley decreased their price target on AlloVir from $32.00 to $27.00 and set an “overweight” rating for the company in a research note on Friday, September 9th. SVB Leerink raised their price objective on AlloVir from $24.00 to $25.00 and gave the company an “outperform” rating in a research report on Monday, November 7th.

AlloVir Stock Down 3.6 %

ALVR opened at $7.45 on Thursday. AlloVir, Inc. has a 12-month low of $3.17 and a 12-month high of $20.68. The stock has a market cap of $694.06 million, a price-to-earnings ratio of -2.66 and a beta of 0.64. The business has a 50 day moving average of $7.98 and a 200-day moving average of $6.31.

Insider Activity

In related news, Director David Hallal sold 600,000 shares of AlloVir stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $8.45, for a total transaction of $5,070,000.00. Following the completion of the sale, the director now directly owns 138,153 shares of the company’s stock, valued at approximately $1,167,392.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Diana Brainard sold 4,515 shares of AlloVir stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $7.27, for a total transaction of $32,824.05. Following the completion of the sale, the chief executive officer now directly owns 633,033 shares of the company’s stock, valued at approximately $4,602,149.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David Hallal sold 600,000 shares of AlloVir stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $8.45, for a total value of $5,070,000.00. Following the sale, the director now directly owns 138,153 shares of the company’s stock, valued at $1,167,392.85. The disclosure for this sale can be found here. Insiders sold a total of 1,041,951 shares of company stock valued at $8,353,010 over the last three months. Insiders own 54.22% of the company’s stock.

AlloVir Profile

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Read More

Want to see what other hedge funds are holding ALVR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AlloVir, Inc. (NASDAQ:ALVRGet Rating).

Institutional Ownership by Quarter for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.